Lotus Pharmaceutical, a composite pharmaceutical company, is expected to ship at least one batch of its anti-leukemia drug this quarter. Analysts predict double-digit quarterly and annual revenue growth for Lotus Pharmaceutical in the second quarter. Of particular interest is the group's first Southeast Asia acquisition, expected to be finalized by the end of the second quarter. This acquisition will not only directly contribute to revenue and profits but also expedite Lotus Pharmaceutical's entry into key Southeast Asian markets.
The Lotus Pharmaceutical management team has previously stated that in addition to developing its own product line, acquisitions and licensing are crucial strategies for diversifying the product portfolio and maximizing channel value. Besides the U.S. and Taiwan markets, Southeast Asia is the next key focus area. The industry anticipates that this Southeast Asian acquisition is primarily for expanding distribution channels. In the second half of the year, Lotus Pharmaceutical is expected to recognize revenue from the newly acquired business. Furthermore, once existing product lines obtain drug approvals in Southeast Asian countries, Lotus Pharmaceutical will leverage the new platform channels to accelerate market penetration.
Resource (mandarin)
